Research Article
Current Trends and Glimpse for All Pharma Global Regulatory Agencies Requirements of Nitrosamine and NDSRIs Impurities in Pharmaceuticals
Author(s): Rashid Azeez*, Kalyani Bhor and Vinod A Bairagi
The USFDA and EMEA announced in July 2018 that N-Nitroso Dimethylamine and N-N-NDMA are concentrated on pharmaceutical medicinal
products and specifically used in case of SARTANS that are used in the treatment of hypertension and angiotensin II receptor blockers, bringing the
seriousness of nitrosamine presence to light. Subsequently, the diabetes medication pioglitazone and the histamine-2 blocker ranitidine were added
to the list. Nitrosamines are created when amines, secondary amide carbamates and urea derivatives react with nitrates and nitrogenous agents.
Nitrogen is at an oxidation state of +3. Pharmaceutical product degradation, catalysts, solvents, chemical reagents, cross-contamination, the
manufacturing process and raw material contamination are some of the causes of nitrosamine presence in pharmaceutical products. Nitrosamine
Impurity is detected using tec.. Read More»
DOI:
10.4172/0975- 413X.16.2.263-273
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report